Expert Interview
A look at the recent FDA approvals for Regeneron's Eylea HD (aflibercept), for macular edema following retinal vein occlusion (RVO) and the addition of a monthly dosing option across all approved indications.
Ticker(s): REGN, RHHBYInstitution: Wills Eye Hospital
- Assistant Professor of Ophthalmology at Thomas Jefferson University and member of the retina service at Wills Eye Hospital.
- Currently manages ~2500 patients with wet age-related macular degeneration.
- Involved as a clinical investigator in several collaborative trials and studies on various conditions including age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, inherited retinal degenerations and pediatric retinal disorders.
Roughly how many patients do you manage with wet amd?
Added By: sara_adminHow many are on Eylea? Eylea HD?
Added By: sara_adminHow impactful has the approval of Eylea HD been on the treatment of your patients?
Added By: sara_adminHave you prescribed an Eylea biosimilar? If not why?
Does an Eylea biosimilar from a large company like Amgen make it more appealing?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
